The pharma industry last month reported 53 deals worth $9.6 billion as compared to the last 12-month average (November 2020 to October 2021) of 97 deals worth $24.7 billion, according to the latest report released by GlobalData.

Novo Nordisk AS to acquire all outstanding shares of Dicerna Pharmaceuticals Inc, including the RNAi research technology platform, for an equity value of $3.3 billion; Organon & Co to acquire Forendo Pharma for a consideration of up to $954 million; and FountainVest Partners’ acquisition of Beijing Zhendong Langdi Pharmaceutical for approximately $900 million were the three major deals that contributed 53.2 per cent of the total deal value during November 2021.

In the report, GlobalData said that the industry reported 105 venture capital (VC) deals worth $4.2 billion in November 2021, compared to the last 12-month average (November 2020 to October 2021) of 173 deals worth $5.2 billion.

Generate Biomedicines Inc raising $370 million in series B round of financing to advance the development of its novel drug generation platform; Acelyrin Inc raising $250 million in series B round of financing to fund licensing and acquisition of additional programmes with a focus on immunology, and accelerate the development of izokibep; and Arbor Biotechnologies Inc raising $215 million in series B financing to advance its lead programmes in liver and CNS diseases, were the major VC deals reported in November 2021, according to the report.